Pharmacogenomic Evaluation of Antihypertensive Responses in Induced Pluripotent Stem (iPS) Cells Study

Completed

Conditions studied: Hypertension

In brief

Patients enrolled in this study will have completed one of the parent studies "Pharmacogenomic Evaluation of Antihypertensive Responses" (PEAR-1 or PEAR-2) evaluating how well their blood pressure was controlled by medication. Patients in the current study will provide a single tube of blood which will be used to create adult stem cells that can be converted into other cell types, like heart or vasculature. Patients will not be asked to return for any follow up visits.

Key facts

Study ID

NCT01943383

Run by

University of Florida

People needed

21

Starts

2013-08-01

Expected to finish

2018-05-01

Last updated by the study team

2018-05-31

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• participation in the parent trial PEAR (201-2005) or PEAR2 (271-2010)
• assigned to a diuretic arm

You may not qualify if…

• no participation in the parent trial PEAR (201-2005) or PEAR2 (271-2010)
• assigned to a beta blocker arm

Where it is running

• University of Florida — Gainesville, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.